Global Pulmonary Hypertension Drugs Market Analysis 2016-2020 and Forecast 2021-2026
Global Pulmonary Hypertension Drugs Market Analysis 2016-2020 and Forecast 2021-2026
The Pulmonary Hypertension Drugs study provides a comprehensive overview of safety standards, market penetration, and innovation pipelines across major economies.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
The global Pulmonary Hypertension Drugs market size is estimated at xxx million USD with a CAGR xx% from 2016-2020 and is expected to reach xxx Million USD in 2021 with a CAGR xx% from 2021 to 2026. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Pulmonary Hypertension Drugs by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
Prostacyclin and prostacyclin analogs
Endothelin receptor antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) inhibitors
Soluble guanylate cyclase (sGC) stimulators
Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):
Bayer
GSK
Arena
Actelion
Pfizer
United Therapeutics
Gilead Sciences
Lung Biotechnology PBC
Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)
Region Coverage (Regional Production, Demand & Forecast by Countries etc.):
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)
1 Industry Overview
1.1 Pulmonary Hypertension Drugs Industry
Figure Pulmonary Hypertension Drugs Industry Chain Structure
1.1.1 Overview
1.1.2 Development of Pulmonary Hypertension Drugs
1.2 Market Segment
1.2.1 Upstream
Table Upstream Segment of Pulmonary Hypertension Drugs
1.2.2 Downstream
Table Application Segment of Pulmonary Hypertension Drugs
Table Global Pulmonary Hypertension Drugs Market 2016-2026, by Application, in USD Million
1.2.3 COVID-19 Impact
1.3 Cost Analysis
2 Industry Environment (PEST Analysis)
2.1 Policy
2.2 Economics
2.3 Sociology
2.4 Technology
3 Pulmonary Hypertension Drugs Market by Type
3.1 By Type
3.1.1 Prostacyclin and prostacyclin analogs
Table Major Company List of Prostacyclin and prostacyclin analogs
3.1.2 Endothelin receptor antagonists (ERAs)
Table Major Company List of Endothelin receptor antagonists (ERAs)
3.1.3 Phosphodiesterase-5 (PDE-5) inhibitors
Table Major Company List of Phosphodiesterase-5 (PDE-5) inhibitors
3.1.4 Soluble guanylate cyclase (sGC) stimulators
Table Major Company List of Soluble guanylate cyclase (sGC) stimulators
3.2 Market Size
Table Global Pulmonary Hypertension Drugs Market 2016-2020, by Type, in USD Million
Figure Global Pulmonary Hypertension Drugs Market Growth 2016-2020, by Type, in USD Million
Table Global Pulmonary Hypertension Drugs Market 2016-2020, by Type, in Volume
Figure Global Pulmonary Hypertension Drugs Market Growth 2016-2020, by Type, in Volume
3.3 Market Forecast
Table Global Pulmonary Hypertension Drugs Market Forecast 2021-2026, by Type, in USD Million
Table Global Pulmonary Hypertension Drugs Market Forecast 2021-2026, by Type, in Volume
4 Major Companies List
4.1 Bayer (Company Profile, Sales Data etc.)
4.1.1 Bayer Profile
Table Bayer Overview List
4.1.2 Bayer Products & Services
4.1.3 Bayer Business Operation Conditions
Table Business Operation of Bayer (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
4.2 GSK (Company Profile, Sales Data etc.)
4.2.1 GSK Profile
Table GSK Overview List
4.2.2 GSK Products & Services
4.2.3 GSK Business Operation Conditions
Table Business Operation of GSK (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
4.3 Arena (Company Profile, Sales Data etc.)
4.3.1 Arena Profile
Table Arena Overview List
4.3.2 Arena Products & Services
4.3.3 Arena Business Operation Conditions
Table Business Operation of Arena (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
4.4 Actelion (Company Profile, Sales Data etc.)
4.4.1 Actelion Profile
Table Actelion Overview List
4.4.2 Actelion Products & Services
4.4.3 Actelion Business Operation Conditions
Table Business Operation of Actelion (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
4.5 Pfizer (Company Profile, Sales Data etc.)
4.5.1 Pfizer Profile
Table Pfizer Overview List
4.5.2 Pfizer Products & Services
4.5.3 Pfizer Business Operation Conditions
Table Business Operation of Pfizer (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
4.6 United Therapeutics (Company Profile, Sales Data etc.)
4.6.1 United Therapeutics Profile
Table United Therapeutics Overview List
4.6.2 United Therapeutics Products & Services
4.6.3 United Therapeutics Business Operation Conditions
Table Business Operation of United Therapeutics (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
4.7 Gilead Sciences (Company Profile, Sales Data etc.)
4.7.1 Gilead Sciences Profile
Table Gilead Sciences Overview List
4.7.2 Gilead Sciences Products & Services
4.7.3 Gilead Sciences Business Operation Conditions
Table Business Operation of Gilead Sciences (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
4.8 Lung Biotechnology PBC (Company Profile, Sales Data etc.)
4.8.1 Lung Biotechnology PBC Profile
Table Lung Biotechnology PBC Overview List
4.8.2 Lung Biotechnology PBC Products & Services
4.8.3 Lung Biotechnology PBC Business Operation Conditions
Table Business Operation of Lung Biotechnology PBC (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
5 Market Competition
5.1 Company Competition
Table Global Pulmonary Hypertension Drugs Sales Revenue 2016-2020, by Company, in USD Million
Table Global Pulmonary Hypertension Drugs Sales Revenue Share 2016-2020, by Company, in USD Million
Figure Global Pulmonary Hypertension Drugs Sales Revenue Share in 2020, by Company, in USD Million
Table Global Pulmonary Hypertension Drugs Sales Volume 2016-2020, by Company, in Volume
Table Global Pulmonary Hypertension Drugs Sales Volume Share 2016-2020, by Company, in Volume
Figure Global Pulmonary Hypertension Drugs Sales Volume Share in 2020, by Company, in Volume
5.2 Regional Market by Company
Figure North America Pulmonary Hypertension Drugs Market Concentration, in 2020
Figure Europe Pulmonary Hypertension Drugs Market Market Concentration, in 2020
Figure Asia-Pacific Pulmonary Hypertension Drugs MMarket Concentration, in 2020
Figure South America Pulmonary Hypertension Drugs Market Concentration, in 2020
Figure Middle East & Africa Pulmonary Hypertension Drugs Market Concentration, in 2020
6 Demand by End Market
6.1 Demand Situation
6.1.1 Demand in Early-stage Drug Candidates (Phase I & Phase II)
Figure Pulmonary Hypertension Drugs Demand in Early-stage Drug Candidates (Phase I & Phase II), 2016-2020, in USD Million
Figure Pulmonary Hypertension Drugs Demand in Early-stage Drug Candidates (Phase I & Phase II), 2016-2020, in Volume
6.1.2 Demand in Late-stage Drug Candidates (Phase III & Registration Phase)
Figure Pulmonary Hypertension Drugs Demand in Late-stage Drug Candidates (Phase III & Registration Phase), 2016-2020, in USD Million
Figure Pulmonary Hypertension Drugs Demand in Late-stage Drug Candidates (Phase III & Registration Phase), 2016-2020, in Volume
6.2 Regional Demand Comparison
Table Regional Demand Comparison List
Table Major Application in Different Regions
6.3 Demand Forecast
Table Pulmonary Hypertension Drugs Demand Forecast 2021-2026, by Application, in USD Million
Figure Pulmonary Hypertension Drugs Market Growth 2021-2026, by Application, in USD Million
Figure Pulmonary Hypertension Drugs Market Share in 2026, by Application, in USD Million
Table Pulmonary Hypertension Drugs Demand Forecast 2021-2026, by Application, in Volume
Table Pulmonary Hypertension Drugs Market Growth 2021-2026, by Application, in Volume
Table Pulmonary Hypertension Drugs Market Share in 2026, by Application, in Volume
6.4 Impact of the COVID-19 on the Demand
7 Region Operation
7.1 Regional Production
Table Pulmonary Hypertension Drugs Production 2016-2020, by Region, in USD Million
Table Pulmonary Hypertension Drugs Production 2016-2020, by Region, in Volume
7.2 Regional Market
Table Global Pulmonary Hypertension Drugs Market 2016-2020, by Region, in USD Million
Table Global Pulmonary Hypertension Drugs Market Share 2016-2020, by Region, in USD Million
Table Global Pulmonary Hypertension Drugs Market 2016-2020, by Region, in Volume
Table Global Pulmonary Hypertension Drugs Market Share 2016-2020, by Region, in Volume
7.3 by Region
7.3.1 North America
7.3.1.1 Overview
Figure North America Pulmonary Hypertension Drugs Market Size and Growth 2016-2020, in USD Million
Figure North America Pulmonary Hypertension Drugs Market Size and Growth 2016-2020, in Volume
7.3.1.2 by Country (U.S., Canada, Mexico)
Table North America Pulmonary Hypertension Drugs Market Size 2016-2020, by Country, in USD Million
Table North America Pulmonary Hypertension Drugs Market Size 2016-2020, by Country, in Volume
7.3.2 Europe
7.3.2.1 Overview
Figure Europe Pulmonary Hypertension Drugs Market Size and Growth 2016-2020, in USD Million
Figure Europe Pulmonary Hypertension Drugs Market Size and Growth 2016-2020, in Volume
7.3.2.2 by Country (Germany, U.K., France, Italy, Russia, Spain etc.)
Table Europe Pulmonary Hypertension Drugs Market Size 2016-2020, by Country, in USD Million
Table Europe Pulmonary Hypertension Drugs Market Size 2016-2020, by Country, in Volume
7.3.3 Asia-Pacific
7.3.3.1 Overview
Figure Asia-Pacific Pulmonary Hypertension Drugs Market Size and Growth 2016-2020, in USD Million
Figure Asia-Pacific Pulmonary Hypertension Drugs Market Size and Growth 2016-2020, in Volume
7.3.3.2 by Country (China, India, Japan, Southeast Asia etc.)
Table Asia-Pacific Pulmonary Hypertension Drugs Market Size 2016-2020, by Country, in USD Million
Table Asia-Pacific Pulmonary Hypertension Drugs Market Size 2016-2020, by Country, in Volume
7.3.4 South America
7.3.4.1 Overview
Figure South America Pulmonary Hypertension Drugs Market Size and Growth 2016-2020, in USD Million
Figure South America Pulmonary Hypertension Drugs Market Size and Growth 2016-2020, in Volume
7.3.4.2 by Country (Brazil, Argentina etc.)
Table South America Pulmonary Hypertension Drugs Market Size 2016-2020, by Country, in USD Million
Table South America Pulmonary Hypertension Drugs Market Size 2016-2020, by Country, in Volume
7.3.5 Middle East & Africa
7.3.5.1 Overview
Figure Middle East & Africa Pulmonary Hypertension Drugs Market Size and Growth 2016-2020, in USD Million
Figure Middle East & Africa Pulmonary Hypertension Drugs Market Size and Growth 2016-2020, in Volume
7.3.5.2 by Country (Saudi Arabia, South Africa etc.)
Table Middle East & Africa Pulmonary Hypertension Drugs Market Size 2016-2020, by Country, in USD Million
Table Middle East & Africa Pulmonary Hypertension Drugs Market Size 2016-2020, by Country, in Volume
7.4 Regional Import & Export
7.5 Regional Forecast
Table Pulmonary Hypertension Drugs Market Forecast 2021-2026, by Region, in USD Million
Table Pulmonary Hypertension Drugs Market Forecast 2021-2026, by Region, in Volume
8 Marketing & Price
8.1 Price and Margin
8.1.1 Price Trends
8.1.2 Factors of Price Change
Table Price Factors List
8.1.3 Manufacturers Gross Margin Analysis
8.2 Marketing Channel
Figure Marketing Channels Overview
9 Research Conclusion
Research Methodology:
Pulmonary Hypertension Drugs Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|